X-Gen Pharmaceuticals Inc. announces that it has entered into an exclusive distribution agreement with Eurand Pharmaceuticals Inc. for the company’s non-branded pancreatic enzyme product (PEP) Pancrelipase. In accordance with the agreement, X-Gen will represent Eurand as its authorized exclusive distribution agent for its currently marketed unbranded product.
Consistent with the April 28, 2004 Federal Register Notification (as supplemented in October 2007), Eurand has both an IND and an NDA on file for a pancreatic enzyme product and is actively seeking regulatory approval.
As Eurand’s exclusive distribution agent, X-Gen will supply the product in four separate strengths. Pancrelipase 4,500 (NDC# 39822-9045-1), Pancrelipase 10,000 (NDC# 39822-9100-1), Pancrelipase 16,000 (NDC# 39822-9160-1) and Pancrelipase 20,000 (NDC# 39822-9200-1). Capsules are orally administered and contain delayed-release microspheres of porcine pancreatic enzyme concentrate, predominantly pancreatic lipase, amylase and protease. For further information about these pancreatic enzyme products, contact X-Gen Pharmaceuticals at (607) 562-2700.
X-Gen Pharmaceuticals specializes in the development and manufacture of pharmaceutical products which serve the healthcare community. X-Gen’s expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids and inhalants. For further information about X-Gen Pharmaceuticals call (866) 390-4411, or visit the web-site at www.x-gen.us.
Contact: X-Gen Pharmaceuticals (866) 390-4411 www.x-gen.us
SOURCE: X-Gen Pharmaceuticals